vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and MGIC INVESTMENT CORP (MTG). Click either name above to swap in a different company.
MGIC INVESTMENT CORP is the larger business by last-quarter revenue ($297.1M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -3.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -1.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
MGIC Investment Corporation NYSE: MTG ("MGIC") is a provider of private mortgage insurance in the United States. The company is headquartered in Milwaukee, Wisconsin.
ESPR vs MTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $297.1M |
| Net Profit | — | $165.3M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 55.6% |
| Revenue YoY | 143.7% | -3.0% |
| Net Profit YoY | — | -10.9% |
| EPS (diluted) | $0.32 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $297.1M | ||
| Q4 25 | $168.4M | $298.7M | ||
| Q3 25 | $87.3M | $304.5M | ||
| Q2 25 | $82.4M | $304.2M | ||
| Q1 25 | $65.0M | $306.2M | ||
| Q4 24 | $69.1M | $301.4M | ||
| Q3 24 | $51.6M | $306.6M | ||
| Q2 24 | $73.8M | $305.3M |
| Q1 26 | — | $165.3M | ||
| Q4 25 | — | $169.3M | ||
| Q3 25 | $-31.3M | $191.1M | ||
| Q2 25 | $-12.7M | $192.5M | ||
| Q1 25 | $-40.5M | $185.5M | ||
| Q4 24 | — | $184.7M | ||
| Q3 24 | $-29.5M | $200.0M | ||
| Q2 24 | $-61.9M | $204.2M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 71.2% | ||
| Q3 25 | -11.4% | 77.2% | ||
| Q2 25 | 8.6% | 80.9% | ||
| Q1 25 | -34.0% | 76.6% | ||
| Q4 24 | -6.4% | 77.9% | ||
| Q3 24 | -31.0% | 82.9% | ||
| Q2 24 | 3.5% | 85.1% |
| Q1 26 | — | 55.6% | ||
| Q4 25 | — | 56.7% | ||
| Q3 25 | -35.9% | 62.8% | ||
| Q2 25 | -15.4% | 63.3% | ||
| Q1 25 | -62.2% | 60.6% | ||
| Q4 24 | — | 61.3% | ||
| Q3 24 | -57.2% | 65.2% | ||
| Q2 24 | -83.9% | 66.9% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.32 | $0.75 | ||
| Q3 25 | $-0.16 | $0.83 | ||
| Q2 25 | $-0.06 | $0.81 | ||
| Q1 25 | $-0.21 | $0.75 | ||
| Q4 24 | $-0.14 | $0.71 | ||
| Q3 24 | $-0.15 | $0.77 | ||
| Q2 24 | $-0.33 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $235.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $5.0B |
| Total Assets | $465.9M | $6.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $235.1M | ||
| Q4 25 | $167.9M | $369.0M | ||
| Q3 25 | $92.4M | $266.9M | ||
| Q2 25 | $86.1M | $294.9M | ||
| Q1 25 | $114.6M | $207.0M | ||
| Q4 24 | $144.8M | $229.5M | ||
| Q3 24 | $144.7M | $288.6M | ||
| Q2 24 | $189.3M | $281.8M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $-302.0M | $5.1B | ||
| Q3 25 | $-451.4M | $5.2B | ||
| Q2 25 | $-433.5M | $5.2B | ||
| Q1 25 | $-426.2M | $5.1B | ||
| Q4 24 | $-388.7M | $5.2B | ||
| Q3 24 | $-370.2M | $5.3B | ||
| Q2 24 | $-344.2M | $5.1B |
| Q1 26 | — | $6.4B | ||
| Q4 25 | $465.9M | $6.6B | ||
| Q3 25 | $364.0M | $6.6B | ||
| Q2 25 | $347.1M | $6.5B | ||
| Q1 25 | $324.0M | $6.5B | ||
| Q4 24 | $343.8M | $6.5B | ||
| Q3 24 | $314.1M | $6.7B | ||
| Q2 24 | $352.3M | $6.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $230.8M | ||
| Q3 25 | $-4.3M | $215.4M | ||
| Q2 25 | $-31.4M | $183.0M | ||
| Q1 25 | $-22.6M | $223.7M | ||
| Q4 24 | $-35.0M | $182.4M | ||
| Q3 24 | $-35.3M | $182.9M | ||
| Q2 24 | $-7.2M | $169.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $230.2M | ||
| Q3 25 | — | $215.1M | ||
| Q2 25 | — | $183.0M | ||
| Q1 25 | — | $223.5M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | $-35.5M | $182.5M | ||
| Q2 24 | $-7.3M | $169.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 77.1% | ||
| Q3 25 | — | 70.6% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 73.0% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | -68.7% | 59.5% | ||
| Q2 24 | -9.9% | 55.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 1.13× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MTG
Segment breakdown not available.
